Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

Viagra was originally tested as a heart medication for angina. Researchers realized its potent side effect when, contrary to typical trial behavior, male participants were reluctant to return the leftover pills and were observed sitting awkwardly to conceal erections. This user behavior signaled a massive alternative market.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

A genetic diagnostics machine was built to speed up patient diagnosis in hospitals. However, its biggest market turned out to be pharmaceutical companies needing to prove drug efficacy. This highlights how true product-market fit can be discovered accidentally in an adjacent, more lucrative market.

Success in drug discovery hinges on a rare, intuitive 'nose for value.' Lengauer likens this to a star athlete who consistently makes the game-winning shot after many attempts. It's an unteachable gift for getting the big decisions right more often than others, especially in a context of repeated failure.

The rapid advancement of ARPIs wasn't just a scientific breakthrough. It was a rare convergence of FDA interest in new endpoints, a deeper biological understanding of castration resistance, and intense industry and academic collaboration that created a uniquely fertile ground for innovation.

The success of enlicitide wasn't a single discovery but was built on a generation's worth of investment in biocatalysis at Merck, starting in the 90s. This demonstrates that world-changing innovation is a slow, consistent build-up of incremental learnings from prior projects, not a sudden eureka moment.

Stelios Papadopoulos argues that major drug breakthroughs are stochastic events driven by individual intuition, luck, and counterintuitive thinking, not predictable R&D systems. He states that if discovery could be systematized by AI or process, no company would have an edge.

After the Viagra project was saved and initial trials proved incredibly effective (9 out of 10 men responding), the team's findings were rejected by The Lancet. The top medical journal deemed the results 'too good to be true,' showing how deep-seated skepticism persists even in the face of strong positive data.